WO2003025176A3 - Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments - Google Patents

Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2003025176A3
WO2003025176A3 PCT/IB2002/004210 IB0204210W WO03025176A3 WO 2003025176 A3 WO2003025176 A3 WO 2003025176A3 IB 0204210 W IB0204210 W IB 0204210W WO 03025176 A3 WO03025176 A3 WO 03025176A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
apoptosis
medicines
reversion
virus resistance
Prior art date
Application number
PCT/IB2002/004210
Other languages
English (en)
Other versions
WO2003025176A2 (fr
WO2003025176A8 (fr
WO2003025176B1 (fr
Inventor
Adam Telerman
Robert Amson
Marius Tuijnder
Original Assignee
Molecular Engines Lab
Adam Telerman
Robert Amson
Marius Tuijnder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engines Lab, Adam Telerman, Robert Amson, Marius Tuijnder filed Critical Molecular Engines Lab
Publication of WO2003025176A2 publication Critical patent/WO2003025176A2/fr
Publication of WO2003025176A3 publication Critical patent/WO2003025176A3/fr
Publication of WO2003025176B1 publication Critical patent/WO2003025176B1/fr
Publication of WO2003025176A8 publication Critical patent/WO2003025176A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne notamment de nouvelles séquences impliquées dans les voies moléculaires de la suppression tumorale, la réversion tumorale, l'apoptose et/ou la résistance aux virus. Elle concerne également l'utilisation de ces séquences ou le traitement contre le cancer, maladies virales, maladies neurodégénératives ainsi qu'en matière de diagnostique ainsi que pour la mise en oeuvre de procédés de criblage de composés à tester. Cette invention a également pour objet des procédés de détection et/ou de dosage des séquences de l'invention ou de leurs produits d'expression dans un prélèvement biologique.
PCT/IB2002/004210 2001-09-17 2002-09-17 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments WO2003025176A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111979 2001-09-17
FR0111979 2001-09-17

Publications (4)

Publication Number Publication Date
WO2003025176A2 WO2003025176A2 (fr) 2003-03-27
WO2003025176A3 true WO2003025176A3 (fr) 2003-05-30
WO2003025176B1 WO2003025176B1 (fr) 2003-08-21
WO2003025176A8 WO2003025176A8 (fr) 2004-03-04

Family

ID=8867343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004210 WO2003025176A2 (fr) 2001-09-17 2002-09-17 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Country Status (1)

Country Link
WO (1) WO2003025176A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5128273B2 (ja) * 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ
US7332597B2 (en) 2004-06-28 2008-02-19 University Of Kentucky Research Foundation Primers and probe to identify mycobacterium tuberculosis complex
WO2010107733A2 (fr) * 2009-03-16 2010-09-23 Curna, Inc. Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022695A2 (fr) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2000008147A1 (fr) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022695A2 (fr) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2000008147A1 (fr) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRENNER SYDNEY ET AL: "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays", NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 18, no. 6, June 2000 (2000-06-01), pages 630 - 634, XP002199492, ISSN: 1087-0156 *
DATABASE EM_HUM [online] EMBL; 11 December 1998 (1998-12-11), XP002234249, Database accession no. AC006159 *
DATABASE EM_MUS [online] EMBL; 20 May 2001 (2001-05-20), XP002234250, Database accession no. BG795595 *
DATABASE EM_NEW [online] EMBL; 24 February 1995 (1995-02-24), XP002234248, Database accession no. D49382 *
KARTMANN BETTINA ET AL: "Novel roles for mammalian septins: From vesicle trafficking to oncogenesis.", JOURNAL OF CELL SCIENCE, vol. 114, no. 5, March 2001 (2001-03-01), pages 839 - 844, XP002234247, ISSN: 0021-9533 *
KINOSHITA MAKOTO ET AL: "Nedd5, a mammalian septin, is a novel cytoskeletal component interacting with actin-based structures.", GENES & DEVELOPMENT, vol. 11, no. 12, 1997, pages 1535 - 1547, XP008014895, ISSN: 0890-9369 *
LONGTINE M S ET AL: "THE SEPTINS: ROLES IN CYTOKINESIS AND OTHER PROCESSES", CURRENT OPINION IN CELL BIOLOGY, vol. 8, no. 1, 1 February 1996 (1996-02-01), pages 106 - 119, XP002038782, ISSN: 0955-0674 *

Also Published As

Publication number Publication date
WO2003025176A2 (fr) 2003-03-27
WO2003025176A8 (fr) 2004-03-04
WO2003025176B1 (fr) 2003-08-21

Similar Documents

Publication Publication Date Title
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
WO2004066941A3 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO1998035693A3 (fr) Detection et modulation d'inhibiteurs de proteines d'apoptose (iap) et de polypeptides anti-apoptotiques apparentes (miap) permettant d'effectuer le diagnostic et le traitement de maladies proliferatives
WO2010015607A3 (fr) Procédé d'évaluation du risque d'un cancer de la bouche chez un humain
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2000043791A3 (fr) Detection rapide et efficace d'une agregation de proteines aberrantes dans des maladies neurodegeneratives
WO2004106495A3 (fr) Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
WO2005059108A3 (fr) Profils d'expression geniques et procedes d'utilisation
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2007058968A3 (fr) Profils d’expression genique et procedes d’utilisation
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2005032495A8 (fr) Profils d'expression genique et leurs methodes d'utilisation
WO2004046332A3 (fr) Genes amplifies impliques dans un cancer
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2003028631A3 (fr) Cibles medicamenteuses destinees a la maladie d'alzheimer et a d'autres maladies associees a une diminution du metabolisme neuronal
WO2008008983A3 (fr) Procédés et acides nucléiques pour des analyses de problèmes de la prolifération cellulaire
WO2002064731A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003040369A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2007071829A3 (fr) Méthodes et moyens relatifs à des maladies
WO2003025176A8 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025175A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030523

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 13/2003 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP